Imunon Inc (IMNN) 뉴스

Form 8-K - Current report

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a...

Form 424B3 - Prospectus [Rule 424(b)(3)]